Today is #MDSAwarenessDay, a time to recognize patients, families and caregivers impacted by myelodysplastic syndrome (MDS). According to @MDSFoundation, an average 33-55 people are diagnosed with MDS every day in the U.S., underscoring the continued need for effective treatment options. At Orca Bio, we remain committed to advancing high-precision cell therapies for patients with MDS and other blood cancers. #CellTherapy #Hematology #Oncology

An inspiring evening with the blood cancer community. We were proud to join @BloodCancerUtd's Light The Night Silicon Valley to honor patients, survivors, caregivers and families affected by blood cancer. Events like these remind us why our work matters and reinforce our commitment to supporting patients and their families as they navigate their cancer journey. #LightTheNight #Hematology #Oncology #CellTherapy

As we continue progressing our pipeline of high-precision cell therapies, we have several openings across commercial, manufacturing, operations and other functions from entry-level to leadership. Interested in a role? Check out our Careers page: orcabio.com/culture-careers/ #CellTherapy #Hematology #Oncology

ICYMI: @ASTCT_Journal recently published data highlighting long-term overall survival outcomes associated with our FDA-approved high-precision cell therapy for allogeneic transplant in people with hematologic malignancies. The three-year findings provide important insight into the potential long-term impact of innovative approaches to improving transplant outcomes. Learn more: orcabio.com/orca-bio-announc… #CellTherapy #Hematology #Oncology

We’re thrilled to be attending @alliancerm's Cell & Gene Meeting on the Mesa October 5-7, where our Co-founder and CEO Nate Fernhoff will speak on our pipeline of high-precision cell therapies and commercialization of our first FDA approved therapy. Learn more about the discussion: meetingonthemesa.com/agenda/ #Hematology #Oncology #CellTherapy

Today is #WorldALLDay, an opportunity to raise awareness of acute lymphoblastic leukemia (ALL) and the ongoing need for innovation on behalf of patients and families. According to @AmericanCancer an estimated over 6,000 new cases of ALL will be diagnosed in the U.S. in 2026, highlighting the continued need for patients to have new and effective treatment options. At Orca Bio, we’re committed to advancing high-precision cell therapies for patients with ALL and other blood cancers. Learn more: orcabio.com/our-pipeline/ #WorldALLDay #CellTherapy #Hematology #Oncology

At Orca Bio, manufacturing is more than infrastructure. It’s a critical part of our mission to expand access to high-precision cell therapies for patients who need them most. Our 100,000-square-foot manufacturing facility was built to support the reliable, consistent delivery of these therapies. As we continue to grow, our manufacturing capabilities remain essential to bringing the promise of cell therapy to more patients. #CellTherapy #Manufacturing #Biotech #Oncology #Hematology #OrcaBio

Today is #WorldLeukemiaDay, a time to raise awareness of leukemia and recognize the patients, families, caregivers and communities impacted by this disease. According to @BloodCancerUtd the fifth leading cause of cancer deaths among adults ages 20-39 is leukemia, underscoring the continued need for new treatment approaches and improved outcomes. At Orca Bio, we remain committed to advancing high-precision cell therapies with the potential to improve outcomes for patients living with leukemia and other blood cancers. Learn more: orcabio.com/our-pipeline/ #WLD26 #CellTherapy #Hematology #Oncology

This #BloodCancerAwarenessMonth, we’re reminded that behind every statistic is a patient, a family and a story. We’re spotlighting Kelly Terell, Orca Account Manager at Orca Bio, whose connection to this mission is deeply personal. After seeing a family member pass away from lymphoma when she was young, Kelly was led to a career in nursing and later cell and gene therapy. That experience continues to shape her work today as she helps inform treatment centers of Orca Bio’s recent FDA approved high-precision cell therapy. Thank you, Kelly, for your commitment to advancing high-precision cell therapies for patients with blood cancers. Learn more: orcabio.com/our-pipeline/ #EmployeeSpotlight #Oncology #Hematology #CellTherapy

We’re looking forward to attending the fourteenth annual meeting of the @SocietyofHemOnc #SOHO where we will present clinical data across our investigational high-precision cell therapy programs. Learn more about our #SOHO2026 presentations: orcabio.com/orca-bio-to-pres… #Hematology #Oncology #CellTherapy